TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06760546: A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)

Sponsor: Rhythm Pharmaceuticals, Inc. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 39 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$2,074,336

Rescue Site Savings

+$1,367,176

Unlock Full NCT06760546 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06760546 Rescue Dossier →